Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types, today announced that preclinical data about its oncolytic Herpes simplex virus (oHSV) immunotherapy platform will be presented at the American Association of Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL. 

Oncorus®, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference

Oncorus®, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference

Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced that its Chief Executive Officer and co-founder, Mitchell H. Finer, PhD, will present a company overview at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 3:30pm Eastern Time. The event will be held in New York at the Lotte New York Palace.

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

Oncorus, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme (GBM), today announced the appointment of Christophe Quéva, Ph.D., as Chief Scientific Officer and Senior Vice President, Research. The company also announced the addition of Eric M. Sullivan as Senior Vice President, Finance & Operations and Treasurer, and Michael Paglia as Vice President, Chemistry, Manufacturing and Controls. 

FOUR CANCER-KILLING VIRUSES TO WATCH IN 2017

FOUR CANCER-KILLING VIRUSES TO WATCH IN 2017

Cancer-killing viruses are specially engineered versions of naturally occurring viruses that are programmed to home in on cancer cells and kill them without harming normal tissues. This is a branch of immuno-oncology that has been overshadowed by more fruitful endeavors, such as the immune checkpoint inhibitors Opdivo (nivolumab) from Bristol-Myers Squibb and Keytruda (pembrolizumab) from Merck, both of which are now certified cancer blockbusters. But several companies are developing cancer-killing viruses, known in the scientific community as “oncolytic” viruses, and some of those efforts are starting to show promise.

Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC

Oncorus, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme (GBM), today announced that Astellas Venture Management LLC (“AVM”), the corporate venture arm of Astellas Pharma Inc., has provided Series A financing support to the company, increasing its Series A proceeds to $61 million. 

Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer

Oncorus, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced the appointment of Cyrus D. Mozayeni, M.D., as President and Chief Business Officer. 

Celgene backs next-gen oncolytic virus startup in $57M Series A

"Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme (GBM). Active strategic investor Celgene ($CELG) participated in the financing, which was led by MPM Capital."

Read the article from FierceBiotech

A Q&A with CEO of Oncorus that just raised $57M to battle cancer

"The Cambridge, Massachusetts, startup launched on Tuesday announcing that it has raised $57 million in a Series A funding round. Oncorus aims to develop a next-generation immunotherapy platform of oncolytic viruses to treat various kinds of tumors, including highly malignant and aggressive cancers such as glioblastoma multiforme."

Read the article from MedCity News.